CINXE.COM

<!DOCTYPE html><html lang="en" class="h-100"><head><meta charset="utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title> UCSF Solid Neoplasm Clinical Trials for 2025 — San Francisco Bay Area</title><meta property="og:title" content="UCSF Solid Neoplasm Clinical Trials — San Francisco Bay Area"><meta name="description" content="Do you qualify for these Solid Neoplasm studies? We offer 11 options."><meta property="og:description" content="Do you qualify for these Solid Neoplasm studies? We offer 11 options."><meta property="og:url" content="https://clinicaltrials.ucsf.edu/solid-neoplasm"><link rel="canonical" href="https://clinicaltrials.ucsf.edu/solid-neoplasm"><meta name="author" content="UCSF"><meta name="generator" content="edu.ucsf.ctsi.rt.trialfinder"><meta name="referrer" content="origin-when-cross-origin"><meta name="google-site-verification" content="JXe923j97sTSgp-6yxsCdd25Muv0wMNfDR27ba3ER8M"><meta name="msvalidate.01" content="4E5209CC6688B86BBDD2FE074176C029"><link rel="shortcut icon" href="https://clinicaltrials.ucsf.edu/assets/local/ucsf/img/favicon.png"><link rel="alternate" type="application/atom+xml" title="UCSF Clinical Trials" href="https://clinicaltrials.ucsf.edu/meta/feed.atom"><meta property="og:type" content="website"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ucsf"><meta property="og:image" content="https://clinicaltrials.ucsf.edu/assets/local/ucsf/img/share-image.jpg"><link rel="stylesheet" href="https://clinicaltrials.ucsf.edu/assets/local/ucsf/ucsf_identity/banners.css"> <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.4.1/dist/css/bootstrap.min.css" integrity="sha256-L/W5Wfqfa0sdBNIKN9cG6QA5F2qx4qICmU2VgLruv9Y=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdn.jsdelivr.net/gh/coliff/bootstrap-rfs@4.3.1/bootstrap-rfs.css" media="screen and (max-width: 1200px)" integrity="sha256-DgOE2c1ekD0TaTyiCQuH2NdeiZ6VifYJdLdfDwq6C+U=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/animate.css@3.7.2/animate.min.css" integrity="sha256-PHcOkPmOshsMBC+vtJdVr5Mwb7r0LkSVJPlPrp/IMpU=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/font-awesome@4.7.0/css/font-awesome.min.css" integrity="sha256-eZrrJcwDc/3uDhsdt61sL2oOBY362qM3lon1gyExkL0=" crossorigin="anonymous"><link rel="stylesheet" href="https://clinicaltrials.ucsf.edu/assets/css/style.css"><link rel="stylesheet" href="https://clinicaltrials.ucsf.edu/assets/local/ucsf/css/style-local.css"> <script src="https://polyfill-fastly.io/v3/polyfill.min.js?features=default%2CObject.assign%2CObject.entries%2CPromise%2CURLSearchParams%2CURL" crossorigin="anonymous" defer></script> <script src="https://cdn.jsdelivr.net/jquery/2.2.4/jquery.min.js" integrity="sha256-BbhdlvQf/xTY9gja0Dq3HiwQF8LaCRTXxZKRutelT44=" crossorigin="anonymous" defer></script><script src="https://cdn.jsdelivr.net/npm/bootstrap@4.4.1/dist/js/bootstrap.bundle.min.js" integrity="sha256-OUFW7hFO0/r5aEGTQOz9F/aXQOt+TwqI1Z4fbVvww04=" crossorigin="anonymous" defer></script> <link rel="dns-prefetch" href="https://www.google.com/"> <script src="https://clinicaltrials.ucsf.edu/assets/js/app.js" defer></script><script>var google_analytics_live_mode=0;var google_analytics_id='UA-1142388-28';var google_analytics_hostname='clinicaltrials.ucsf.edu';if(google_analytics_id&&google_analytics_hostname&&window.location&&window.location.hostname&&window.location.hostname===google_analytics_hostname){google_analytics_live_mode=1}var google_analytics_js_url='https://www.google-analytics.com/analytics_debug.js';if(google_analytics_live_mode){google_analytics_js_url='https://www.google-analytics.com/analytics.js'}(function(c,h,e,b,f,a,d){c['GoogleAnalyticsObject']=f;c[f]=c[f]||function(){(c[f].q=c[f].q||[]).push(arguments)},c[f].l=1*new Date();a=h.createElement(e),d=h.getElementsByTagName(e)[0];a.async=1;a.src=b;d.parentNode.insertBefore(a,d)})(window,document,'script',google_analytics_js_url,'ga');if(!google_analytics_live_mode){}if(google_analytics_live_mode){ga('create',google_analytics_id,'auto')}else{ga('set','sendHitTask',null)}ga('require','outboundLinkTracker');ga('require','pageVisibilityTracker');ga('send','pageview');var s_opt={};s_opt['s_apid']='53G5XLK75T';s_opt['s_ixnm']='trials_ucsf';s_opt['s_ixky']='6e038166fd15da69c2ed075975c00816';s_opt['s_plac']=undefined;s_opt['s_mlti']=false;var _paq=window._paq=window._paq||[];_paq.push(['setTrackerUrl','https://clinicaltrials.ucsf.edu/action/t/l/']);_paq.push(['setSiteId','9']);_paq.push(['setCustomDimension',1,'condition\u002dpage']);_paq.push(['trackPageView']);_paq.push(['enableLinkTracking']);_paq.push(['enableHeartBeatTimer']);(function(){var a=document,g=a.createElement('script'),s=a.getElementsByTagName('script')[0];g.type='text/javascript';g.async=true;g.src='https://clinicaltrials.ucsf.edu/action/t/js/';s.parentNode.insertBefore(g,s)})();</script><script async src="https://cdn.jsdelivr.net/npm/autotrack@1.0.3/autotrack.js" integrity="sha256-MFv0PQKCj7HPlACiJTgQ+3rHnOSY1a510jcQGGwtemQ=" crossorigin="anonymous"></script><script type="application/ld+json"> { "@context": "https://schema.org/", "@type": "WebSite", "publisher": { "@type": "MedicalOrganization", "name": "UCSF", "address": "San Francisco Bay Area", "url": "https://www.ucsf.edu/", "logo": "https://s2.googleusercontent.com/s2/favicons?domain_url=https%3A%2F%2Fwww.ucsf.edu%2F", "sameAs": [ "https://twitter.com/@ucsf" ] } } </script><meta name="ahrefs-site-verification" content="5f73483e1fea16c76799e8797bf1b843c1c0cda17921ee5e1670f98bd81223f4"><link rel="dns-prefetch" href="https://researcherprofiles.org/"></head><body class="condition-page bg-light d-flex flex-column"> <a id="skip-to-main-content" class="sr-only sr-only-focusable" href="#content">Skip to main content</a> <header id="header" class="mb-4"><div id="ucsf-banner-nav"><div class="container-fluid"><div class="top-header-container" style="max-width: 100%"><div><ul class="menu"><li class="first"><a href="https://www.ucsf.edu">University of California San Francisco</a></li><li><a href="https://www.ucsfhealth.org/">UCSF Medical Center</a></li><li><a href="https://www.ucsf.edu/search">Search UCSF</a></li><li><a href="https://www.ucsf.edu/about">About UCSF</a></li></ul></div></div></div></div><nav class="navbar navbar-expand-md navbar-light d-print"> <a class="navbar-brand" href="https://clinicaltrials.ucsf.edu/"> <img src="https://clinicaltrials.ucsf.edu/assets/local/ucsf/img/site-name.png" alt="UCSF Clinical Trials"> </a> <button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbar--menu--primary-content" aria-controls="navbar--menu--primary-content" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> <div class="collapse navbar-collapse justify-content-end" id="navbar--menu--primary-content"><ul class="navbar-nav"> <li class="nav-item" id="navbar--menu--home"> <a class="nav-link" href="https://clinicaltrials.ucsf.edu/">Search</a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="https://clinicaltrials.ucsf.edu/browse/" id="navbar--menu--browse-dropdown-link" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> Browse </a> <div class="dropdown-menu dropdown-menu-right" aria-labelledby="navbar--menu--browse-dropdown-link"> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/">All trials</a> <div class="dropdown-divider"></div><div class="dropdown-header">Trials for…</div> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/healthy">Healthy volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/pediatric" title="Pediatric clinical trials, for people under age 18">People under 18</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/geriatric" title="Geriatric clinical trials, for people over age 65">People over 65</a> <div class="dropdown-divider"></div><div class="dropdown-header">Trials seeking…</div> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/black" title="Trials that may be particularly relevant to Black volunteers"> Black volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/chinese" title="Trials that may be particularly relevant to Chinese volunteers"> Chinese volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/korean" title="Trials that may be particularly relevant to Korean volunteers"> Korean volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/latinx" title="Trials that may be particularly relevant to Latinx volunteers"> Latinx volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/lgbtqia" title="Trials that may be particularly relevant to LGBTQIA+ volunteers"> LGBTQIA+ volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/mena" title="Trials that may be particularly relevant to Middle Eastern or North African volunteers"> Middle Eastern or North African volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/native-american" title="Trials that may be particularly relevant to Native American volunteers"> Native American volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/native-hawaiian" title="Trials that may be particularly relevant to Native Hawaiian volunteers"> Native Hawaiian volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/south-asian" title="Trials that may be particularly relevant to South Asian volunteers"> South Asian volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/veteran" title="Trials that may be particularly relevant to Veteran volunteers"> Veteran volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/vietnamese" title="Trials that may be particularly relevant to Vietnamese volunteers"> Vietnamese volunteers</a> </div></li> <li class="nav-item" id="navbar--menu--equity" data-nosnippet> <a class="nav-link" href="https://clinicaltrials.ucsf.edu/about/equity">Equity <span class="d-none d-xl-inline">in Research</span></a></a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="https://clinicaltrials.ucsf.edu/about/" id="navbar--menu--about-dropdown-link" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> About <span class="d-none d-lg-inline">the site</span> </a> <div class="dropdown-menu dropdown-menu-right" aria-labelledby="navbar--menu--about-dropdown-link"> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/about/">About UCSF Clinical Trials</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/about/for-researchers">For Researchers</a> <div class="dropdown-divider"></div><div class="dropdown-header">Learn more in…</div> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/about/chinese" data-nosnippet>Chinese</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/about/spanish" data-nosnippet>Spanish</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/about/vietnamese" data-nosnippet>Vietnamese</a> </div></li></ul></div> </nav><nav class="breadcrumb-and-search-bar navbar navbar-expand navbar-light d-print d-flex justify-content-between"> <div><ol class="breadcrumb navbar-text my-0 pl-1" itemscope="itemscope" itemtype="https://schema.org/BreadcrumbList"><li itemprop="itemListElement" itemscope itemtype="https://schema.org/ListItem"> <a href="https://clinicaltrials.ucsf.edu/" itemscope="itemscope" itemprop="item" itemtype="https://schema.org/Thing" id="navbar--breadcrumb--link-1"> Home <meta itemprop="name" content="UCSF Clinical Trials"> </a> <meta itemprop="position" content="1"></li><li class="active">Solid Neoplasm Studies</li></ol></div> <div><div class="d-none d-md-block navbar-text"><form method="GET" action="https://clinicaltrials.ucsf.edu/" class="form-inline my-1" role="search"> <label class="sr-only" for="header-search--input">Search</label> <input id="header-search--input" name="q" type="text" class="form-control form-control-sm" placeholder="Search UCSF clinical trials" title="Search clinical trials at UCSF"> <input class="sr-only form-control-sm btn btn-sm btn-secondary" type="submit" value="Search trials"> </form></div></div> </nav></header><main id="content" class="mx-1 mx-md-0"> <div class="container-md" itemscope itemtype="https://schema.org/WebPage"><div id="condition-header"><h1 class="mb-2" itemprop="headline"> <strong>Solid Neoplasm</strong> clinical trials at UCSF </h1><p class="h3 mb-5 text-muted" id="condition-header--clinical-trial-counts"><span data-nosnippet> 35 in progress, 11 open to eligible people </span></p><div class="row"><p id="condition-header--clinical-trial-portfolio-description" class="trials-list-header--explanatory-paragraph col col-md-9 col-lg-8" itemprop="description speakable"> A solid neoplasm is a cluster of abnormal cells growing in the body. UCSF is examining the effects of a new drug, Tegavivint, on recurrent tumors. They are also testing how well Ceralasertib works alone or with other drugs. UCSF collects samples for research on HIV/AIDS-related cancers. </p></div></div><div class="row"> <div class="col col-md-9 col-lg-8 "> <div class="trials-list--filter-container card bg-light text-center mb-3 d-none d-print-none" data-nosnippet><div class="card-body p-1"><span class="trials-list--filter-main-heading d-none d-md-inline"> Showing <span class="trials-list--number-of-trials-shown" aria-live="assertive"></span> trials for </span><div class="btn-group btn-group-sm btn-group-toggle ml-3" role="group" aria-label="Filter trials by sex/gender" data-toggle="buttons"> <label class="btn btn-light mr-1 active"> <input checked type="radio" name="trials-list--filter-sex" data-class-wanted=""> <i class="fa fa-male d-none d-lg-inline" aria-hidden="true"></i><i class="fa fa-female d-none d-lg-inline" aria-hidden="true"></i> All </label> <label class="btn btn-light mr-1"> <input type="radio" name="trials-list--filter-sex" data-class-wanted="trials-list--trial-open-to-sex-female"> <i class="fa fa-female d-none d-lg-inline" aria-hidden="true"></i> Female </label> <label class="btn btn-light mr-1"> <input type="radio" name="trials-list--filter-sex" data-class-wanted="trials-list--trial-open-to-sex-male"> <i class="fa fa-male d-none d-lg-inline" aria-hidden="true"></i> Male </label> </div><div class="btn-group btn-group-sm btn-group-toggle ml-3" role="group" aria-label="Filter trials by age range" data-toggle="buttons"> <label class="btn btn-light active"><input checked type="radio" name="trials-list--filter-age" data-class-wanted="">All ages</label> <label class="btn btn-light"><input type="radio" name="trials-list--filter-age" data-class-wanted="trials-list--trial-open-to-age-under-18">Under 18</label> <label class="btn btn-light"><input type="radio" name="trials-list--filter-age" data-class-wanted="trials-list--trial-open-to-age-18-and-over">Over 18</label> </div></div></div> <ul class="list-unstyled" id="trials-list"><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04870944" class="stretched-link">CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 12 months to 30 years </p><div class="trials-list--trial-summary"><p>This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Drugs, such as CBL0137, block signals passed from one molecule to another inside a cell. Blocking these signals can affect many functions of the cell, including cell division and cell death, and may kill cancer cells.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center-Mission Bay"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03682289" class="stretched-link">Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This phase II trial studies how well ceralasertib, am Ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor, works alone or in combination with olaparib or durvalumab in treating participants with renal cell carcinoma (RCC), urothelial carcinoma, all pancreatic cancers, endometrial cancer, and other solid tumors excluding clear cell ovarian cancer that have spread to nearby tissue or lymph nodes or other parts of the body. ATR kinase inhibitor AZD6738 and olaparib or durvalumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not known if giving ATR kinase inhibitor AZD6738 with or without olaparib or durvalumab may work better in treating participants with solid tumors.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-open-to-healthy "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05641961" class="stretched-link">Mobile App to Help Survivors of Childhood Cancer Navigate Long-Term Follow-Up Care</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to all eligible people </p><div class="trials-list--trial-summary"><p>This clinical trial studies the effectiveness of a newly developed survivorship mobile application (app) designed for survivors, or their caregivers, of childhood cancer to help them better navigate long-term follow-up care. The survivorship app provides survivors access to their treatment history and follow-up recommendations, improves knowledge of their diagnosis, treatment, risks, and recommended follow-up care by using a message notification. The ability to quickly connect and establish care planning may enhance adherence to recommended follow-up.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04939090" class="stretched-link">Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This phase III trial compares the effects of olanzapine versus megestrol acetate in treating loss of appetite in patients with cancer that has spread to other places in the body (advanced). Olanzapine may stimulate and increase appetite. This study aims to find out if olanzapine is better than the usual approach (megestrol acetate) for stimulating appetite and preventing weight loss.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="Zuckerberg San Francisco General Hospital"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94110"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05564377" class="stretched-link">Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to all eligible people </p><div class="trials-list--trial-summary"><p>This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center-Mission Bay"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04851119" class="stretched-link">Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 12 months to 30 years </p><div class="trials-list--trial-summary"><p>This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells by blocking the signals passed from one molecule to another inside a cell that tell a cell to grow.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center-Mission Bay"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05286801" class="stretched-link">Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 12 months and up </p><div class="trials-list--trial-summary"><p>This phase I/II trial studies how well tiragolumab and atezolizumab works when given to children and adults with SMARCB1 or SMARCA4 deficient tumors that have either come back (relapsed) or do not respond to therapy (refractory). SMARCB1 or SMARCA4 deficiency means that tumor cells are missing the SMARCB1 and SMARCA4 genes, seen with some aggressive cancers that are typically hard to treat. Immunotherapy with monoclonal antibodies, such as tiragolumab and atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center-Mission Bay"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05663502" class="stretched-link">Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This study collects blood and tissue samples for research of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)-related cancers. Collecting blood and tissue samples and studying biomarkers in the laboratory may help doctors to learn how are biologic or genetic factors related to HIV and cancers that occur commonly in people living with HIV.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94110"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05228275" class="stretched-link">Immunologic Response Following COVID-19 Vaccination in Children, Adolescents, and Young Adults With Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 6 months to 37 years </p><div class="trials-list--trial-summary"><p>This study evaluates immunologic response following COVID-19 vaccination in children, adolescents, and young adults with cancer. Vaccines work by stimulating the body's immune cells to respond against a specific disease. The immune response produces protection from that disease. Effects from cancer and from treatments for cancer can reduce the body's natural disease fighting ability (called immunity). Factors such as vaccine type, timing of vaccine dosing related to treatment for cancer and number of vaccine doses or "boosts" (extra vaccine shots) may strengthen or diminish the body's protective immune response. This study may help researchers learn more about how the body's immune system responds to the COVID-19 vaccine when the vaccination is given during or after cancer treatment.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Benioff Children's Hospital Oakland"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">Oakland</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94609"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT02402244" class="stretched-link">Project: Every Child for Younger Patients With Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages up to 25 years </p><div class="trials-list--trial-summary"><p>This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Benioff Children's Hospital Oakland"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">Oakland</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94609"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05359237" class="stretched-link">Vincristine Pharmacokinetics in Infants</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> open to eligible people ages up to 12 years </p><div class="trials-list--trial-summary"><p>This pilot trial compares drug exposure levels using a new method for dosing vincristine in infants and young children compared to the standard dosing method based on body surface area (BSA) in older children. Vincristine is an anticancer drug used to a variety of childhood cancers. The doses anticancer drugs in children must be adjusted based on the size of the child because children vary significantly in size (height, weight, and BSA) and ability to metabolize drugs from infancy to adolescence. The dose of most anticancer drugs is adjusted to BSA, which is calculated from a patient's weight and height. However, infants and young children have more severe side effects if the BSA is used to calculate their dose, so new dosing models have to be made to safely give anticancer drugs to the youngest patients. This new method uses a BSA-banded approach to determine the dose. Collecting blood samples before and after a dose of the drug will help researchers determine whether this new vincristine dosing method results in equivalent drug levels in the blood over time in infants and young children compared to older children.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center-Mission Bay"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT02498613" class="stretched-link">Cediranib in Combination With Olaparib in Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be removed by surgery (unresectable), including breast cancer, non-small cell lung cancer, small cell lung cancer, and pancreatic cancer. Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may also block the flow of oxygen to the tumor, and may help make the tumor more sensitive to olaparib.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center-Mount Zion"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04773782" class="stretched-link">Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a Phase 1/2, multicenter, open-label trial of avapritinib in participants 2 to < 18 years of age with advanced relapsed/refractory (R/R) solid tumors, including central nervous system (CNS) tumors, that harbor a PDGFRA and/or KIT mutation (including non-synonymous point mutations, insertions, and deletions) or amplification, or DMG-H3K27a who have no available curative treatment options. This is a single-arm trial in which all participants will receive avapritinib. The study consists of 2 parts: dose confirmation, safety, and PK (Part 1) and initial efficacy, safety, and PK at the Part 2 recommended dose (Part 2).</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF, Benioff Children's Hospital"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94518"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05711667" class="stretched-link">Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase III trial determines whether taking prophylactic letermovir will reduce the likelihood of infection with cytomegalovirus (CMV) in children and adolescents after stem cell transplant. The treatments used to prepare for HCT reduce the body's natural infection-fighting ability and increase the likelihood of an infection with a virus called cytomegalovirus. "Prophylaxis" means to take a drug to prevent a disease or side effect. Letermovir is an antiviral drug that stops cytomegalovirus from multiplying and may prevent cytomegalovirus infection and make the disease less severe.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Benioff Children's Hospital Oakland"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">Oakland</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94609"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT06602999" class="stretched-link">Nutritional Needs of Cancer Survivors With Nutrition Insecurity</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not yet accepting patients </p><div class="trials-list--trial-summary"><p>This clinical trial studies whether the use of a grocery delivery service (Instacart) and nutrition navigation improves food insecurity in cancer survivors. The American Cancer Society recommends a normal body mass index, regular physical activity, and a healthy diet for cancer patients. Following these guidelines may help prevent deaths among cancer patients, but few cancer patients follow them. One reason for not following the guidelines could be due to the lack of consistent access to sufficient quantities of affordable, nutritious food for an active, healthy life (food insecurity). Instacart provides users access to foods that fall under the nutrition plan for cancer survivors that can be purchased and delivered to the user's home from many different grocery stores. Nutrition navigation provides support to cancer survivors via weekly check ins to help with following nutrition guidelines and assist with ordering groceries on the Instacart platform. Using a grocery delivery service, such as Instacart, and nutrition navigation may help improve food insecurity in cancer survivors.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="Zuckerberg San Francisco General"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94110"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT02867592" class="stretched-link">Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth and tumor blood vessel growth.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Benioff Children's Hospital Oakland"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">Oakland</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94609"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03742895" class="stretched-link">Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0007)"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05071209" class="stretched-link">Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase I/II trial tests the safety, best dose, and whether elimusertib works in treating patients with solid tumors that have come back (relapsed) or does not respond to treatment (refractory). Elimusertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center-Mission Bay"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03213652" class="stretched-link">Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II Pediatric MATCH treatment trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back (recurrent) or does not respond to treatment (refractory) and may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Ensartinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Benioff Children's Hospital Oakland"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">Oakland</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94609"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03210714" class="stretched-link">Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with FGFR mutations that have spread to other places in the body and have come back or do not respond to treatment. Erdafitinib may stop the growth of cancer cells with FGFR mutations by blocking some of the enzymes needed for cell growth.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Benioff Children's Hospital Oakland"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">Oakland</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94609"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04195555" class="stretched-link">Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II Pediatric MATCH trial studies how well ivosidenib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have IDH1 genetic alterations (mutations). Ivosidenib may block the growth of cancer cells that have specific genetic changes in an important signaling pathway called the IDH pathway.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Benioff Children's Hospital Oakland"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">Oakland</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94609"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03834961" class="stretched-link">Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II trial studies the side effects and how well larotrectinib works in treating patients with previously untreated TRK fusion solid tumors and TRK fusion acute leukemia that has come back. Larotrectinib may stop the growth of cancer cells with TRK fusions by blocking the TRK enzymes needed for cell growth.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center-Mission Bay"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03213704" class="stretched-link">Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II Pediatric MATCH trial studies how well larotrectinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with NTRK fusions that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and have come back (relapased) or does not respond to treatment (refractory). Larotrectinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Benioff Children's Hospital Oakland"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">Oakland</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94609"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT02595931" class="stretched-link">M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase I trial studies the side effects and best dose of M6620 and irinotecan hydrochloride in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). M6620 and irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center-Mount Zion"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04089358" class="stretched-link">Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase III trial compares a multi-component mobile health and social media physical activity intervention versus wearing a physical activity tracker alone among adolescent and young adult childhood cancer survivors. Regular physical activity helps maintain healthy weight, energy levels, and health. Adolescents and young adults who complete treatment for cancer are often less active. They may gain weight and have more health problems compared to people the same age who have not had treatment for cancer. Comparing the 2 programs will help researchers learn how to increase physical activity levels over time and also how changes in physical activity levels affect health and quality of life over time.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Benioff Children's Hospital Oakland"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">Oakland</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94609"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03030378" class="stretched-link">Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase I trial studies the side effects and best dose of pembrolizumab and recombinant interleukin-12 in treating patients with solid tumors. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Recombinant interleukin-12 may kill tumor cells by blocking blood flow to the tumor and by stimulating white blood cells to kill tumor cells. Giving pembrolizumab and recombinant interleukin-12 may work better than giving pembrolizumab alone in treating patients with solid tumors.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center-Mount Zion"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05103358" class="stretched-link">Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Helen Diller Family Comprehensive Cancer Center"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04320888" class="stretched-link">Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II pediatric MATCH treatment trial studies how well selpercatinib works in treating patients with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the body (advanced), lymphomas, or histiocytic disorders that have activating RET gene alterations. Selpercatinib may block the growth of cancer cells that have specific genetic changes in an important signaling pathway (called the RET pathway) and may reduce tumor size.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Benioff Children's Hospital Oakland"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">Oakland</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94609"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03155620" class="stretched-link">Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Benioff Children's Hospital Oakland"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">Oakland</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94609"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03284385" class="stretched-link">Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II trial studies how well adavosertib works in treating patients with SETD2-deficient solid tumors that have spread to other places in the body (advanced/metastatic). Adavosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center-Mount Zion"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04284774" class="stretched-link">Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a genetic alteration in the gene HRAS. Tipifarnib may block the growth of cancer cells that have specific genetic changes in a gene called HRAS and may reduce tumor size.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Benioff Children's Hospital Oakland"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">Oakland</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94609"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03698994" class="stretched-link">Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II Pediatric MATCH trial studies how well ulixertinib works in treating patients with solid tumors that have spread to other places in the body (advanced), non-Hodgkin lymphoma, or histiocytic disorders that have a genetic alteration (mutation) in a signaling pathway called MAPK. A signaling pathway consists of a group of molecules in a cell that control one or more cell functions. Genes in the MAPK pathway are frequently mutated in many types of cancers. Ulixertinib may stop the growth of cancer cells that have mutations in the MAPK pathway.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Benioff Children's Hospital Oakland"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">Oakland</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94609"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03223753" class="stretched-link">Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This randomized clinical phase III trial studies how well web-based physical activity intervention works in improving long term health in children and adolescents with cancer. Regular physical activity after receiving treatment for cancer may help to maintain a healthy weight and improve energy levels and overall health.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Benioff Children's Hospital Oakland"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">Oakland</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94609"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04387656" class="stretched-link">NCI COVID-19 in Cancer Patients, NCCAPS Study</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This study collects blood samples, medical information, and medical images from patients who are being treated for cancer and have a positive test for SARS CoV-2, the new coronavirus that causes the disease called COVID-19. Collecting blood samples, medical information, and medical images may help researchers determine how COVID-19 affects the outcomes of patients undergoing cancer treatment and how having cancer affects COVID-19.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center-Mission Bay"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT06587100" class="stretched-link">Wearable Activity Tracking to Curb Hospitalizations</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not yet accepting patients </p><div class="trials-list--trial-summary"><p>This study is being done to collect patient generated health data to predict the risk of patients needing emergency department visits or hospitalization before, during. and after receiving radiation therapy.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> </span></p></div></div></li></ul><div><p class="text-muted small comma-list"> Our lead scientists for Solid Neoplasm research studies include <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/pamela.munster" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Pamela Munster</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/rahul.aggarwal" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Rahul Aggarwal</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/arun.rangaswami" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Arun A. Rangaswami</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/jennifer.michlitsch" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Jennifer G. Michlitsch</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/sabine.mueller" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Sabine Mueller</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/robert.goldsby" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Robert Goldsby, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/julian.hong" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Julian Hong, MD, MS</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/kieuhoa.vo" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Kieuhoa T. Vo</span></a></span>. </p><p class="text-muted small">Last updated: <time itemprop="dateModified" datetime="2025-02-05">February 5, 2025</time></p></div></div> <div class="col-md-3 col-lg-3 offset-lg-1"><aside class="d-print-none"><h3 class="h5 mt-5" role="complementary">Related Links</h3><ul><li><a href="https://www.ucsfhealth.org/find-a-doctor/" rel="nofollow">UCSF Health doctors</a></li><li><a href="https://www.ucsf.edu/search?search=Solid%20Neoplasm" rel="nofollow">Solid Neoplasm resources at UCSF</a></li></ul></aside></div> </div> </div> </main><footer class="mt-auto" role="contentinfo" data-nosnippet><div id="ucsf--footer--body"><div class="container" data-nosnippet><div class="row mb-1 d-print-none"><div class="col-12 text-center text-md-left"> We use cookies to operate our website, analyze performance, and improve your experience on our site. <a href="https://www.ucsf.edu/website-privacy-policy" target="_blank">Learn more.</a> </div></div><div class="row"><div class="col-md-6 text-center text-md-left"><p class="my-0"> © The Regents of the University of California </p></div><div class="col-md-6 text-center text-md-right pt-3 pt-md-0"> <a href="https://websites.ucsf.edu/digital-accessibility" target="_blank">Accessibility</a> <a href="https://www.ucsf.edu/website-privacy-policy" target="_blank">Privacy Policy</a> <a href="https://websites.ucsf.edu/website-terms-use" target="_blank">Terms of Use</a> </div></div></div></div></footer><script>(function(){var b=document.createElement('script');b.type='text/javascript';b.async=true;b.src='//siteimproveanalytics.com/js/siteanalyze_8343.js';var a=document.getElementsByTagName('script')[0];a.parentNode.insertBefore(b,a)})();</script></body></html>